| 郭清保,谢曼丽,杨彦龙,马 涛,李立宏.脑血疏口服液联合依达拉奉对高血压脑出血的治疗效果及对血清IL-6，IL-1β，MMP-9的影响[J].现代生物医学进展英文版,2017,17(21):4071-4074. |
| 脑血疏口服液联合依达拉奉对高血压脑出血的治疗效果及对血清IL-6，IL-1β，MMP-9的影响 |
| Effects of Cerebral Hemorrhagic Oral Liquid Combined with Edaravone on Hypertensive Cerebral Hemorrhage and Serum IL-6, IL-1β and MMP-9 Levels |
| Received:March 14, 2017 Revised:March 30, 2017 |
| DOI：10.13241/j.cnki.pmb.2017.21.017 |
| 中文关键词: 脑血疏口服液 依达拉奉 高血压 脑出血 |
| 英文关键词: Cerebral hemorrhagic oral solution Edaravone Hypertension Cerebral hemorrhage |
| 基金项目:陕西省自然科学基金项目(09K1259) |
|
| Hits: 345 |
| Download times: 199 |
| 中文摘要: |
| 摘要 目的：研究脑血疏口服液联合依达拉奉对高血压脑出血的治疗效果及对血清白介素-6(IL-6)、IL-1β、基质金属蛋白酶-9(MMP-9)的影响。方法：选取2014年10月至2016年9月我院收治的102例高血压脑出血患者，根据入院顺序分为观察组和对照组，51例每组。对照组使用常规治疗，观察组在此基础上采取脑血疏口服液联合依达拉奉完成治疗。比较两组患者临床疗效，神经功能评分、血肿周围水肿量、血肿量，血清IL-6、IL-1β、MMP-9水平。结果：治疗后，观察组临床总有效率显著高于对照组[94.12%(48/51)比78.43%(40/51)](P<0.05)；神经功能评分、血肿量、周围水肿量显著低于对照组[(11.04±1.21)分、(8.65±0.54)mL、(5.87±0.54)mL比(19.87±1.76)分、(13.56±1.23)mL、(9.65±0.92)mL](P<0.05)；血清IL-6、IL-1β、MMP-9水平低于对照组[(8.98±0.87)ng/mL、(12.34±1.21)ng/L、(74.21±8.42)ng/L比(11.21±1.02)ng/mL、(23.87±2.37)ng/L、(92.17±9.86)ng/L](P<0.05)。两组患者不良反应的发生率比较差异无统计学意义(P>0.05)。结论：脑血疏口服液联合依达拉奉治疗高血压脑出血的临床疗效明显优于常规治疗，可能与其有效降低患者血清IL-6、IL-1β、MMP-9水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To study the effects of cerebral hemorrhagic oral liquid combined with edaravone on the hypertensive cere- bral hemorrhage and the serum Interleukin-6 (IL-6), IL-1β, matrix metalloproteinase-9 (MMP-9) levels. Methods: 102 patients with hy- pertensive intracerebral hemorrhage admitted in our hospital from October 2014 to September 2016 were selected and divided into the observation group and the control group according to the order of admission. The control group was treated with conventional therapy, while the observation group was treated with cerebral hemorrhagic oral solution combined with edaravone on the basis of control group. The clinical efficacy, neurological score, hematoma edema, hematoma volume, serum IL-6, IL-1β and MMP-9 levels were compared between the two groups. Results: After treatment, the total effective rate of observation group was significantly higher than that of the con- trol group [94.12% (48/51) vs. 78.43% (40/51)] (P<0.05). The neurological function score, hematoma volume and edema of observation group were significantly lower than those of the control group [(11.04±1.21) points, (8.65±0.54) mL, (5.87±0.54) mL vs. (19.87±1.76) points, (13.56±1.23) mL, (9.65±0.92) mL](P<0.05). The levels of serum IL-6, IL-1β and MMP-9 of observation group were lower than those of the control group [(8.98±0.87) ng/mL, (12.34±1.21) ng/L, (74.21±8.42)ng/L vs. (11.21±1.02)ng/mL, (23.87±2.37) ng/L, (92.17±9.86) ng/L] (P<0.05). There was no significant difference in the incidence of adverse reaction between the two groups (P>0.05). Conclusion: Cerebrospinal fluid combined with edaravone was more effective in the treatment of hypertensive intracerebral hemorrhage than the conventional treatment, which might be related to the reduce of serum IL-6, IL-1β and MMP-9 levels. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
